What Produces GLP-1 Naturally? Genetic Biomarkers & Origins

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 (glucagon-like peptide-1) is produced naturally by intestinal L-cells located primarily in the ileum and colon. These specialized cells secrete GLP-1 in response to glucose, amino acids, and fatty acids entering the small intestine—a process known as nutrient sensing that occurs within minutes of eating.

For many individuals, naturally occurring GLP-1 levels may not be sufficient to maintain healthy weight regulation or blood sugar control. Understanding your body's endogenous GLP-1 production capacity—including how biomarkers and genetic predispositions influence this pathway—can help you and your provider evaluate whether GLP-1 therapy is appropriate for your specific metabolic profile.

The Anatomy and Physiology of GLP-1 Production

L-cells are neuroendocrine cells distributed throughout the small and large intestine, with the highest concentration in the distal ileum and rectum. Upon nutrient exposure, these cells release GLP-1 into the bloodstream, where it acts on receptors in the brain, pancreas, and gut to regulate satiety, insulin secretion, and glucose homeostasis.

The GLP-1 signaling cascade is rapid: L-cells detect nutrient composition within seconds and release GLP-1 within minutes. However, baseline GLP-1 production varies significantly between individuals based on L-cell density, nutrient sensitivity, and genetic variation in the GLP1R gene itself.

Individual Variation in GLP-1 Production: A Biomarker and Genetic Framework

Not all individuals produce GLP-1 at the same rate or in response to the same nutrient triggers. Biomarkers such as fasting GLP-1 levels, postprandial GLP-1 response, and insulin secretion patterns reveal significant inter-individual differences. Additionally, common genetic variants in related pathways influence how efficiently your L-cells produce and release GLP-1.

Factor	Clinical Significance
Fasting GLP-1 Level	Baseline GLP-1 production capacity; lower levels may indicate reduced L-cell function or nutrient sensitivity
Postprandial GLP-1 Response	How much GLP-1 your L-cells release after eating; blunted response associated with weight gain and metabolic dysfunction
GLP1R rs6923761 Variant	Genetic predisposition affecting GLP-1 receptor expression and signaling efficiency; may influence natural GLP-1 pathway sensitivity
Intestinal L-Cell Density	Number and distribution of L-cells in the gut; varies by genetics, age, and metabolic health; influences maximum GLP-1 production capacity

Why Some Individuals Require Exogenous GLP-1 Therapy

Individuals with obesity, type 2 diabetes, or metabolic syndrome often exhibit attenuated endogenous GLP-1 production or impaired L-cell nutrient sensing. Research demonstrates that obese subjects produce less GLP-1 in response to oral glucose compared to lean controls—a deficit that contributes to dysregulated appetite and glucose control.

When endogenous GLP-1 production is insufficient, exogenous GLP-1 receptor agonists—whether compounded semaglutide, tirzepatide, or other formulations—bypass the body's L-cell limitation and provide pharmacologic GLP-1 signaling. This approach directly addresses the underlying physiological deficit rather than relying on enhanced nutrient sensing.

Genetic Predispositions and Treatment Considerations

Multiple genetic variants influence GLP-1 pathway function, including GIPR rs1800437, and FTO rs9939609. These variants affect L-cell function, GLP-1 receptor sensitivity, appetite regulation, and fat-mass distribution. Understanding your genetic predispositions may provide context for why endogenous GLP-1 production alone has not met your metabolic goals.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in the GLP-1 signaling pathway—including GIPR rs1800437—to provide biomarker context about your natural GLP-1 production and receptor sensitivity. This information may help provide context about whether exogenous GLP-1 therapy aligns with your genetic predispositions, though it should be interpreted with a qualified healthcare provider.

The genetic test reveals predispositions in peptide pathways relevant to GLP-1 signaling, not exact medication response or guaranteed outcomes. Variants in related genes may influence your baseline GLP-1 production capacity, L-cell nutrient sensing efficiency, and how your body's GLP-1 receptors respond to therapy. Understanding these predispositions can support more targeted treatment conversations.

PlexusDx offers the Precision Peptide Genetic Test for $298, alongside compounded GLP-1 options including oral semaglutide $289/mo month-to-month, or from $249/mo on the 6-month plan, compounded semaglutide injection $189/mo month-to-month, or from $149/mo on the 6-month plan, and microdose GLP-1 protocols from $129/month. These offerings, sourced from licensed 503A compounding pharmacies, allow your provider to personalize therapy based on both genetic context and clinical response.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Where in the body does the article say GLP-1 is actually manufactured?

In intestinal L-cells, which the post describes as neuroendocrine cells distributed through the small and large intestine with the highest concentration in the distal ileum. It says they secrete GLP-1 into the bloodstream in response to glucose, amino acids, and fatty acids arriving in the small intestine, after which it acts on receptors in the brain, pancreas, and gut.

How quickly does the article say the L-cell response happens after eating?

Very quickly. The post says L-cells detect nutrient composition within seconds and release GLP-1 within minutes of eating, a process it calls nutrient sensing. It uses that speed to frame GLP-1 as a real-time signal about what has just been consumed rather than a slow background hormone, which is why meal composition matters to the response.

What does the article's factor table say a blunted post-meal response signals?

The table says a blunted postprandial GLP-1 response, meaning how much the L-cells release after eating, is associated with weight gain and metabolic dysfunction. It pairs that with fasting GLP-1 level as a measure of baseline production capacity, where lower readings may indicate reduced L-cell function or weaker nutrient sensitivity.

Why does the article say natural GLP-1 output differs in people with obesity?

It says people with obesity, type 2 diabetes, or metabolic syndrome often show attenuated endogenous GLP-1 production or impaired L-cell nutrient sensing. The post cites research finding that subjects with obesity produce less GLP-1 in response to oral glucose than lean controls, and describes that deficit as contributing to dysregulated appetite and glucose control.

How does the article describe what a prescribed GLP-1 does that food cannot?

It says exogenous GLP-1 receptor agonists bypass the body's L-cell limitation and supply pharmacologic GLP-1 signaling directly. The article's argument is that this addresses the underlying physiological deficit rather than depending on improved nutrient sensing, which is the ceiling that diet-based approaches run into when endogenous production is already impaired.

Related Reading

• Glp 1 Hormone
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• How Do Genetic Variations Impact Glp 1 Response
• Maximus Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.